Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study

Libert, Y.; Borghgraef, C.; Beguin, Yves; Delvaux, N.; DEVOS, Martine; Doyen, C.; Dubruille, S.; Etienne, Anne-Marie; Liénard, A.; Merckaert, I.; Reynaert, C.; Slachmuylder, J.-L.; Straetmans, N.; Van Den Neste, E.; Bron, D.; Razavi, D.

doi:10.1002/pon.4424

Article (Scientific journals)

Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study

Libert, Y.; Borghgraef, C.; Beguin, Yves et al.

2017 • In Psycho-oncology, 26 (12), p. 2086-2093

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/220479

DOI
10.1002/pon.4424

PubMed
28316129

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Sujet agé cognitive function 2-PsychoOncol.pdf

Publisher postprint (255.1 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Article; FCSR IR test; Hospital Anxiety and Depression Scale

Abstract :

[en] Objective: Despite the well-known negative impacts of cancer and anticancer therapies on cognitive performance, little is known about the cognitive compensatory processes of older patients with cancer. This study was designed to investigate the cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy. Methods: We assessed 89 consecutive patients (age ≥ 65 y) without severe cognitive impairment and 89 age-, sex-, and education level-matched healthy controls. Cognitive compensatory processes were investigated by (1) comparing cognitive performance of patients and healthy controls in novel (first exposure to cognitive tasks) and non-novel (second exposure to the same cognitive tasks) contexts, and (2) assessing psychological factors that may facilitate or inhibit cognitive performance, such as motivation, psychological distress, and perceived cognitive performance. We assessed cognitive performance with the Trail-Making, Digit Span and FCSR-IR tests, psychological distress with the Hospital Anxiety and Depression Scale, and perceived cognitive performance with the FACT-Cog questionnaire. Results: In novel and non-novel contexts, average cognitive performances of healthy controls were higher than those of patients and were associated with motivation. Cognitive performance of patients was not associated with investigated psychological factors in the novel context but was associated with motivation and psychological distress in the non-novel context. Conclusions: Older, clinically fit patients with hematologic malignancies undergoing chemotherapy demonstrated lower cognitive compensatory processes compared to healthy controls. Reducing distress and increasing motivation may improve cognitive compensatory processes of patients in non-novel contexts. Copyright © 2017 John Wiley & Sons, Ltd.

Disciplines :

Hematology

Author, co-author :

Libert, Y.; Université Libre de Bruxelles, Brussels, Belgium

Borghgraef, C.; Université Libre de Bruxelles, Brussels, Belgium

Beguin, Yves ; Université de Liège - ULiège > GIGA-R : Hématologie

Delvaux, N.; Université Libre de Bruxelles, Brussels, Belgium

DEVOS, Martine ; Centre Hospitalier Universitaire de Liège - CHU > Centre d'oncologie

Doyen, C.; Université Catholique de Louvain, Yvoir, Belgium

Dubruille, S.; Université Libre de Bruxelles, Brussels, Belgium

Etienne, Anne-Marie ; Université de Liège - ULiège > Département de Psychologie > Psychologie de la santé

Liénard, A.; Université Libre de Bruxelles - ULB

Merckaert, I.; Université Libre de Bruxelles, Brussels, Belgium

More authors (6 more)

Language :

English

Title :

Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study

Publication date :

2017

Journal title :

Psycho-oncology

ISSN :

1057-9249

eISSN :

1099-1611

Publisher :

John Wiley and Sons Ltd

Volume :

Issue :

Pages :

2086-2093

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 February 2018

Statistics

Number of views

127 (2 by ULiège)

Number of downloads

238 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Butler KM, Mcdaniel MA, Dornburg CC, Price AL, Roediger HL. Age differences in veridical and false recall are not inevitable: the role of frontal lobe function. Psychon Bull Rev. 2004;11(5):921-925.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292-2299.
van Dam FS, Boogerd W, Schagen SB et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210-218.
Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses. 2006;67(2):212-215.
Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192-201.
Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13(1):61-66.
Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080-1086.
Kvale EA, Clay OJ, Ross-Meadows LA et al. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial. Eur J Cancer Care. 2010;19(1):110-117.
Yamada TH, Denburg NL, Beglinger LJ, Schultz SK. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci. 2010;22(1):48-54.
Mohile SG, Lacy M, Rodin M et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2010;75(2):152-159.
Hurria A, Goldfarb S, Rosen C et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006;98(3):343-348.
Extermann M. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol. 2004;49(1):69-75.
Chen H, Cantor A, Meyer J et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 2003;97(4):1107-1114.
Buckwalter JG, Crooks VC, Petitti DB. Cognitive performance of older women who have survived cancer. Int J Neurosci. 2005;115(9):1307-1314.
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866-3870.
Schrijnemaekers AM, de Jager CA, Hogervorst E, Budge MM. Cases with mild cognitive impairment and Alzheimer's disease fail to benefit from repeated exposure to episodic memory tests as compared with controls. J Clin Exp Neuropsychol. 2006;28(3):438-455.
Posner MI, Snyder CR. Attention and Cognitive Control. In: Balota D & Marsh E, eds. Cognitive Psychology: Key Readings. New York and Hove: Psychology Press; 2004:205-223.
Arndt J, Das E, Schagen SB, Reid-Arndt SA, Cameron LD, Ahles TA. Broadening the cancer and cognition landscape: the role of selfregulatory challenges. Psychooncology. 2014;23(1):1-8.
Suchy Y, Kraybill ML, Franchow E. Practice effect and beyond: reaction to novelty as an independent predictor of cognitive decline among older adults. J Int Neuropsychol Soc. 2011;17(01):101-111.
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185(12):914-919.
Roehrig B, Hoeffken K, Pientka L, Wedding U. How many and which items of activities of daily living (ADL) and instrumental activities of daily living (IADL) are necessary for screening. Crit Rev Oncol Hematol. 2007;62(2):164-171.
Wechsler D. Wechsler Adult Intelligence Scale–Fourth Edition (WAIS–IV). NCS Pearson: San Antonio, TX; 2008.
Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3(1):13-36.
Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271-276.
Joly F, Lange M, Rigal O et al. French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3. Support Care Cancer. 2012;20(12):3297-3305.
Wagner LI, Sweet J, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy–cognitive function instrument. J Support Oncol. 2009;7(6):W32-W39.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.
Williams AM, Zent CS, Janelsins MC. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol. 2016;174(6):835-846.
Asher A, Myers JS. The effect of cancer treatment on cognitive function. Clin Adv Hematol Oncol. 2015;13(7):441-450.